Capstone Investment Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capstone Investment Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,907	Closed	-$1.66M	–	1617
2025 Q3	$1.66M	Buy	+5,907	New	+$1.61M	﹤0.01%	836
2024 Q2	–	Sell	-2,293	Closed	-$793K	–	2091
2024 Q1	$793K	Buy	+2,293	New	+$754K	﹤0.01%	1285
2023 Q4	–	Sell	-601	Closed	-$188K	–	2122
2023 Q3	$215K	Buy	+601	New	+$232K	﹤0.01%	1778
2017 Q4	–	Sell	-1,300	Closed	-$288K	–	503
2017 Q3	$288K	Buy	+1,300	New	+$293K	0.01%	403

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capstone Investment Advisors's BIO Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2025, closing a stake of 5,907 shares — an estimated $1.66M sold.

Capstone Investment Advisors first reported a position in BIO in Q3 2017 and held it in 4 quarters. The position peaked at $1.66M in Q3 2025. 396 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

Capstone Investment Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2025 after selling out during the quarter.
Capstone Investment Advisors sold 5,907 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $1.66M.
Capstone Investment Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2017 and held it in 4 quarters.
Capstone Investment Advisors's Bio-Rad Laboratories Class A position peaked at $1.66M in Q3 2025.
396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.